Latest News - Moderna
Top Corporates Hub
Moderna
Moderna eyes international markets as growth driver, says Bank of America
08.04.2026 16:58
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to analysts at Bank of America. They noted that the 2025-2026 vaccine season is winding down, and the company’s litigation...
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension
08.04.2026 16:14
Moderna (NasdaqGS:MRNA) reported positive Phase 3 clinical data for its investigational influenza vaccine mRNA-1010 and RSV vaccine mRESVIA. The company is presenting these results, including late breaking sessions, at a major international infectious disease congress. Early readouts point to favorable immune responses and safety profiles across both programs. The data add clinical support for Moderna's push into seasonal respiratory vaccines beyond its existing COVID-19 product. For...
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
08.04.2026 13:00
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
MRNY: Strong Income Run Masks Rising Downside Risk
08.04.2026 10:56
YieldMax MRNA Option Income Strategy ETF is rated a Sell due to heightened downside risk and overvalued pipeline optimism. Read more on MRNY ETF here.
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035 - Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas
07.04.2026 16:01
Messenger RNA Market Messenger RNA Market Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Messenger RNA Market - A Global and Regional Analysis: Application and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The messenger RNA (mRNA) market is undergoing significant expansion, driven by its versatile approach in treating and preventing diseases through innovative mRNA-based vaccines and therapeutics. This growth trajectory, projected to
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes
06.04.2026 03:43
Moderna, Inc. (NASDAQ:MRNA) is among the stocks in focus as Jim Cramer reviewed the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter. Cramer highlighted the bullish environment around the stock, as he said: Finally, aside from the data center plays and the commodity plays, there’s a one-off in the […]
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump
04.04.2026 08:07
Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing the stock. After recent volatility, the stock sits at US$49.20, with returns of 59.4% year to date and 95.9% over the last year, alongside weaker 3 and 5 year figures of 68.9% and 65.1% declines. Recent headlines around Moderna have continued to focus on its position in pharmaceuticals and biotech, keeping attention on how its pipeline and partnerships might affect long...
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
01.04.2026 12:07
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Moderna (MRNA) Valuation Check As Patent Dispute Settlement And Cancer Therapy Pivot Refocus Investor Attention
01.04.2026 07:15
Moderna (MRNA) is back in focus after settling a large patent dispute and outlining its push into individualized cancer therapies, a shift that coincides with increased attention on its broader vaccine pipeline. See our latest analysis for Moderna. At a share price of US$50.80, Moderna has seen a 72.26% 90 day share price return and an 87.04% 1 year total shareholder return, while the 3 year total shareholder return is down 67.54%. This suggests that recent momentum has picked up after a...
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
29.03.2026 12:15
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates both opportunity and risk that investors need to understand clearly right now. The fund carries over $8 billion in assets across 150+ holdings, ... MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance
Moderna’s Diverging Flu Vaccine Rulings May Shift mRNA Growth Story
29.03.2026 02:04
European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines to review the same vaccine despite positive clinical trial data. Moderna's CEO signals a potential pullback in US based late stage trials after the FDA decision. Political scrutiny of FDA processes and the departure of a key FDA official add uncertainty for US biotech. Regulatory divergence is influencing biotech investment flows toward Europe and other...
New TPA Report Finds FDA Costs Soaring, Drug Rejections Rising
26.03.2026 17:24
Today, the Taxpayers Protection Alliance (TPA) released a report, "Blocking Breakthroughs: Delays and Denials at the FDA," highlighting the many issues with the Food and Drug Administration's (FDA's) drug approval process. The report comes amid continued controversy over the agency insisting on unrealistic and ethically-fraught criteria for approvals and walking back a bizarre decision to refuse to examine an application by Moderna for its first mRNA seasonal flu vaccine. Fortunately, FDA Center
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?
26.03.2026 15:30
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
America is handing its mRNA lead to China—and RFK Jr. is to blame
26.03.2026 11:30
Political interference is driving biotech investment overseas, and U.S. patients and workers will pay the price.
Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...'
20.03.2026 07:18
Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of legal and institutional turbulence over vaccine policy.
Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?
17.03.2026 12:00
The FDA's embattled vaccine chief, Vinay Prasad, will exit the agency. But that doesn't mean biotech stocks should breathe easy.
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul
17.03.2026 07:19
A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the latest on the ACIP legal challenge here.
GSK’s RSV vaccine wins broader FDA clearance
13.03.2026 11:54
The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost uptake of a shot that’s posted flattening sales after an initially strong launch.
3 Healthcare Stocks We’re Skeptical Of
13.03.2026 09:31
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 3.8%, nearly mirrorring the S&P 500.
Stocks to Watch Monday: Moderna, Live Nation, Pfizer, Hims & Hers
09.03.2026 11:42
↘️ Carnival (CCL), American Airlines (AAL) and United Airlines (UAL): Carriers and cruise operators are expected to face higher fuel costs due to the energy-price surge. Shares fell in premarket trading.